ImmunityBio's ANKTIVA Gains Saudi FDA Green Light, Securing Key MENA Partnerships for Bladder and Lung Cancer Launch

Approval in Saudi Arabia Accelerates ANKTIVA's MENA Expansion with New Distribution Deals

ImmunityBio, Inc. (NASDAQ: IBRX) is moving quickly to bring its breakthrough immunotherapy, ANKTIVA, to patients in Saudi Arabia following formal approval by the Saudi Food and Drug Authority (SFDA). Under new partnerships with Biopharma and Cigalah Healthcare—two heavyweights in pharmaceutical distribution across the Middle East and North Africa (MENA)—ANKTIVA will be commercially available for bladder and lung cancers, a move that could reshape access to innovative oncology treatments in the region.

The company’s establishment of a wholly owned subsidiary in Saudi Arabia marks a strategic effort to support physicians, healthcare systems, and patients, while also setting the stage for ANKTIVA’s regional expansion. ANKTIVA is expected to be available within the next two months, with regulatory discussions underway in the United Arab Emirates to extend its indications and reach.

Strategic Partnerships and Regulatory Milestones Position ANKTIVA for Regional Impact

Saudi Arabia and the broader MENA region represent significant untapped potential for oncology innovation, with particularly high unmet needs in lung and bladder cancers. Lung cancer remains a major health challenge in Saudi Arabia, ranking as the third most prevalent cancer among men over 45. At the same time, bladder cancer rates are among the world’s highest in Lebanon, Syria, and Egypt, underscoring the urgency for new treatments.

ImmunityBio’s commercial agreement entrusts Biopharma and Cigalah with the distribution of ANKTIVA for two indications. First, as a combination therapy with Bacillus Calmette-Gurin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer. Second, as an add-on to checkpoint inhibitors for patients whose metastatic non-small cell lung cancer has progressed after standard therapies. Saudi FDA’s accelerated approval is based on promising clinical data, opening the door for broader approval contingent on confirmatory trials.

ANKTIVA’s Science Delivers Novel Mechanism in Immune-Driven Therapy

ANKTIVA (nogapendekin alfa inbakicept) is a first-in-class IL-15 agonist, designed to activate natural killer (NK) and T cells for durable cancer control. The drug is based on interleukin-15 (IL-15) biology—crucial for the immune system’s ability to recognize and eliminate tumor cells. ANKTIVA works by overcoming tumor escape mechanisms and reinvigorating immune memory, supporting longer-lasting patient responses. Its approval as part of combination regimens addresses difficult-to-treat populations and underscores the shift toward next-generation immunotherapies in oncology.

Market Implications: Rapid Rollout and Scalable Platform for New Indications

For ImmunityBio, the Saudi approval and local subsidiary mark important steps toward scaling ANKTIVA’s market presence. The immediate goal is rapid commercial availability—distribution will begin within 60 days. Importantly, regulatory pathways are being pursued in other MENA markets, including the UAE, Qatar, and Egypt, suggesting a regional growth trajectory fueled by unmet patient need. The company’s distribution partners bring extensive networks and experience in bringing advanced therapies to healthcare providers across the Middle East, a critical advantage as ImmunityBio eyes further expansion.

Looking Ahead: Expansion Opportunities Come with Execution Risks

While the approval and partnerships signal strong opportunity for ImmunityBio, a number of challenges remain. Market adoption, pricing, and regulatory conditions will play a major role in ANKTIVA’s trajectory across the MENA region. In particular, investors and analysts will be watching for progress in post-approval studies, reimbursement wins, and execution by local subsidiaries and partners. ImmunityBio’s own regulatory filings highlight these as ongoing risks that may affect the drug’s long-term position.

Key Takeaway: The approval and upcoming commercial rollout of ANKTIVA in Saudi Arabia mark a significant advance in ImmunityBio’s regional ambitions, opening new paths to address serious cancer needs in the Middle East. With experienced distribution partners, the company stands poised for accelerated growth in 2026 and beyond—but will need to clear regulatory and operational hurdles to realize this potential. Investors may want to monitor additional approvals, launch progress, and updates on market uptake as ImmunityBio seeks to deliver on its promise in the MENA oncology space.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI